<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445822</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-CML-paed 016</org_study_id>
    <secondary_id>EudraCT: 2007-001339-69</secondary_id>
    <nct_id>NCT00445822</nct_id>
  </id_info>
  <brief_title>Registration of Children With CML and Treatment With Imatinib</brief_title>
  <acronym>CML-paed II</acronym>
  <official_title>Protocol for Standardized Diagnostic Procedures, Registration, and Treatment Recommendations in Children and Adolescents With Philadelphia Chromosome-positive Chronic Myeloid Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Academy of Wroclaw, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leiden, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Society for Pediatric Hematology and Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uniuversity of Genua, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Newly diagnosed pediatric patients (age &lt; 19 years) with bcr-abl-positive CML will be treated
      with imatinib. Serial monitoring of treatment response is performed in one month intervals
      during the first three months of treatment and in three months intervals thereafter. Patients
      with non-response, poor response (either molecular, cytogenetic, or hematologic non-/poor
      response) or progress of the disease while under imatinib treatment will stop imatinib and
      undergo stem cell transplantation. All responders to imatinib treatment with an HLA matched
      donor will undergo stem cell transplantation not later than 2 years after diagnosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indication:

      Newly diagnosed pediatric patients with bcr-abl-positive CML.

      Design:

      Multicenter, non-randomized, open, prospective clinical trial.

      Objectives:

      Primary:

      - assessment of antileukemic activity of imatinib in children and adolescents with
      Philadelphia chromosome-positive chronic myeloid leukemia

      Secondary:

        -  assessment of the time-to event-efficacy variables

        -  correlation of the quality of haematological, cytogenetical and molecular remission in
           children and adolescents with CML on ongoing imatinib therapy with survival

        -  safety of imatinib

      Endpoints:

      Primary:

      - rate of haematological, cytogenetical and molecular remissions

      Secondary:

        -  time to progression

        -  duration of chronic phase

        -  time to loss of response

        -  overall survival

        -  assessment of treatment-related toxicities in children and adolescents.

      Inclusion criteria:

      Newly diagnosed Ph+ or bcr-abl-positive CML- Male and female patients aged 0 to 18 years-
      Written informed consent

      Exclusion criteria:

        -  CML without bcr-abl rearrangement detectable by PCR

        -  Pretreatment with Interferon alpha or any other cytostatic drug with the exception of
           hydroxyurea or anagrelide (Note: anagrelide is not approved in Germany for treatment of
           CML). However, these patients may be registered as observational patients.

        -  Any other severe underlying disease beside CML.

        -  Age &gt; 18 years

        -  Pregnant or lactating women

        -  Subjects unlikely to comply with the requirements of the protocol

      Number of patients to be enrolled: 150

      Recruitment period: 5 years

      Treatment period: 2 years

      Planned start of study: 2007

      Planned end of study: 2013
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myeloid Leukemia, Chronic</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone Marrow and blood smears
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pts younger than 19 years with PH+ CML are recruited from primary care clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed Ph+ or bcr-abl-positive CML

          -  Male and female patients aged 0 to 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  CML without bcr-abl rearrangement detectable by PCR

          -  Pretreatment with Interferon alpha or any other cytostatic drug with the exception of
             hydroxyurea or anagrelide (Note: anagrelide is not approved in Germany for treatment
             of CML). However, these patients may be registered as observational patients.

          -  Any other severe underlying disease beside CML.

          -  Age &gt; 18 years- Pregnant or lactating women

          -  Subjects unlikely to comply with the requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meinolf Suttorp, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital, Dpt. Ped. Hemato-Oncology, Technical University of Dresden, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meinolf Suttorp, Prof. Dr.</last_name>
    <phone>+49 351 458</phone>
    <phone_ext>3522</phone_ext>
    <email>meinolf.suttorp@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xenia Graehlert, Dr.</last_name>
    <phone>+49 351 458</phone>
    <phone_ext>5160</phone_ext>
    <email>grahlert@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hopsital, Technical University of Dresden, Fetscherstr. 74</name>
      <address>
        <city>Dresden</city>
        <state>Saxonia</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meinolf Suttorp, Prof. Dr.</last_name>
      <phone>+49 351 458</phone>
      <phone_ext>3522</phone_ext>
      <email>meinolf.suttorp@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN, Gadner H, Sufliarska S, Stary J, Gschaidmeier H, Guilhot F, Suttorp M. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006 Feb;20(2):187-92.</citation>
    <PMID>16341042</PMID>
  </reference>
  <reference>
    <citation>Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J, Suttorp M. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Eur J Haematol. 2009 Feb;82(2):112-8. doi: 10.1111/j.1600-0609.2008.01170.x. Epub 2008 Nov 10.</citation>
    <PMID>19067742</PMID>
  </reference>
  <reference>
    <citation>Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S40-6. doi: 10.1038/bmt.2008.282. Review.</citation>
    <PMID>18978743</PMID>
  </reference>
  <reference>
    <citation>Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica. 2009 Aug;94(8):1177-9. doi: 10.3324/haematol.2009.008359. Epub 2009 Jun 22.</citation>
    <PMID>19546438</PMID>
  </reference>
  <reference>
    <citation>Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb HJ, Kröger N, Zander AR. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004. Ann Hematol. 2009 Dec;88(12):1237-47. doi: 10.1007/s00277-009-0737-3. Epub 2009 Mar 25.</citation>
    <PMID>19319532</PMID>
  </reference>
  <reference>
    <citation>Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program. 2010;2010:368-76. doi: 10.1182/asheducation-2010.1.368. Review.</citation>
    <PMID>21239821</PMID>
  </reference>
  <reference>
    <citation>Suttorp M, Yaniv I, Schultz KR. Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S115-22. doi: 10.1016/j.bbmt.2010.09.003.</citation>
    <PMID>21195300</PMID>
  </reference>
  <reference>
    <citation>Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, Dilloo D, Kremens B, Kabisch H, Führer M, Zintl F, Göbel U, Klingebiel T. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr. 2009 Nov-Dec;221(6):351-7. doi: 10.1055/s-0029-1239529. Epub 2009 Nov 4.</citation>
    <PMID>19890786</PMID>
  </reference>
  <reference>
    <citation>Suttorp M, Tauer JT, Millot F: Chronic myeloid leukemia in children: diagnostics and management Onkologie (CZ) 5(2):12-15, 2011</citation>
  </reference>
  <results_reference>
    <citation>Suttorp M, Thiede C, Tauer JT, Range U, Schlegelberger B, von Neuhoff N. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia. Haematologica. 2010 May;95(5):852-3. doi: 10.3324/haematol.2009.019224. Epub 2010 Feb 9.</citation>
    <PMID>20145269</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2007</study_first_submitted>
  <study_first_submitted_qc>March 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Meinolf Suttorp</name_title>
    <organization>Universitätskinderklinik Dresden</organization>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>Children</keyword>
  <keyword>Imatinib</keyword>
  <keyword>bcr-abl</keyword>
  <keyword>Response</keyword>
  <keyword>Imatinib mesylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

